Tomáš Pavlík1, Ondřej Májek1, Tomáš Büchler2, Rostislav Vyzula3, Jiří Petera4, Miroslav Ryska5, Aleš Ryška6, David Cibula7, Marko Babjuk8, Jitka Abrahámová2, Jiří Vorlíček3, Jan Mužík1, Ladislav Dušek9. 1. Institute of Biostatistics and Analyses, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic. 2. Department of Oncology and 1st Faculty of Medicine, Thomayer Hospital and Charles University, Vídeňská 800, 140 59 Prague, Czech Republic. 3. Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic. 4. Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic. 5. Department of Surgery and 2nd Faculty of Medicine, Central Military Hospital and Charles University, U Vojenské nemocnice 1200, 169 02 Prague, Czech Republic. 6. The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic. 7. Gynaecological Oncologic Centre and 1st Faculty of Medicine, General University Hospital and Charles University, Apolinářská 18, 128 51 Prague, Czech Republic. 8. Department of Urology and 2nd Faculty of Medicine, University Hospital Motol and Charles University, V Úvalu 84, 150 06 Prague, Czech Republic. 9. Institute of Biostatistics and Analyses, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic. Electronic address: dusek@iba.muni.cz.
Abstract
BACKGROUND: The objective of this study was to assess trends in overall and in stage-specific 5-year relative survival rates of the Czech cancer patients between periods 2000-2004 and 2005-2008. METHODS: All Czech cancer patients diagnosed between 1995 and 2008 were included in the analysis. Period analysis was employed to calculate 5-year relative survival for 21 cancers. RESULTS: Significant improvements in crude 5-year relative survival for 14 of 21 assessed types of cancer, including the most frequent diagnoses, such as, colorectal, prostate, breast, lung, kidney, pancreatic, and bladder cancer and melanoma, were identified. Moreover, in case of colorectal, lung, and prostate cancer, improvement in stage-specific 5-year relative survival was confirmed as statistically significant for all clinical stages. No diagnosis showed significant decrease in the 5-year relative survival. However, the 5-year relative survival remained poor in patients with metastatic cancers at diagnosis, particularly in case of liver, pancreatic, lung, and oesophageal cancer. CONCLUSIONS: The cancer-specific outcomes in the Czech Republic are improving. Nevertheless, despite the overall significant improvement in 5-year relative survival of most of the cancer diagnoses, the high proportion of patients primarily diagnosed with metastatic cancer still represents a substantial challenge for prevention and early detection.
BACKGROUND: The objective of this study was to assess trends in overall and in stage-specific 5-year relative survival rates of the Czech cancerpatients between periods 2000-2004 and 2005-2008. METHODS: All Czech cancerpatients diagnosed between 1995 and 2008 were included in the analysis. Period analysis was employed to calculate 5-year relative survival for 21 cancers. RESULTS: Significant improvements in crude 5-year relative survival for 14 of 21 assessed types of cancer, including the most frequent diagnoses, such as, colorectal, prostate, breast, lung, kidney, pancreatic, and bladder cancer and melanoma, were identified. Moreover, in case of colorectal, lung, and prostate cancer, improvement in stage-specific 5-year relative survival was confirmed as statistically significant for all clinical stages. No diagnosis showed significant decrease in the 5-year relative survival. However, the 5-year relative survival remained poor in patients with metastatic cancers at diagnosis, particularly in case of liver, pancreatic, lung, and oesophageal cancer. CONCLUSIONS: The cancer-specific outcomes in the Czech Republic are improving. Nevertheless, despite the overall significant improvement in 5-year relative survival of most of the cancer diagnoses, the high proportion of patients primarily diagnosed with metastatic cancer still represents a substantial challenge for prevention and early detection.
Authors: Katerina Kubackova; Bohuslav Melichar; Zbynek Bortlicek; Tomas Pavlik; Alexandr Poprach; Marek Svoboda; Radek Lakomy; Rostislav Vyzula; Igor Kiss; Ladislav Dusek; Jana Prausova; Tomas Buchler Journal: Target Oncol Date: 2015-12 Impact factor: 4.493
Authors: Jennifer L Caswell-Jin; Sylvia K Plevritis; Lu Tian; Christopher J Cadham; Cong Xu; Natasha K Stout; George W Sledge; Jeanne S Mandelblatt; Allison W Kurian Journal: JNCI Cancer Spectr Date: 2018-12-24
Authors: Martin Lovecek; Marketa Janatova; Pavel Skalicky; Tomas Zemanek; Roman Havlik; Jiri Ehrmann; Ondrej Strouhal; Petra Zemankova; Klara Lhotova; Marianna Borecka; Jana Soukupova; Hana Svebisova; Pavel Soucek; Viktor Hlavac; Zdenek Kleibl; Cestmir Neoral; Bohuslav Melichar; Beatrice Mohelnikova-Duchonova Journal: Cancer Manag Res Date: 2019-01-10 Impact factor: 3.989